<DOC>
	<DOCNO>NCT02074956</DOCNO>
	<brief_summary>This Phase I study conduct randomized , double-blind , dose-escalation study five group healthy adult male female subject BCG-vaccinated , HIV-negative , evidence tuberculosis infection . Since BCG-vaccinated individual target population AERAS 404 might indicate , AERAS 404 administered individual already vaccinate BCG</brief_summary>
	<brief_title>A Phase I Study Evaluate Safety Immunogenicity AERAS 404 Administered Adults</brief_title>
	<detailed_description>Sixty subject sequentially enrol one five study group ( i.e. , Group 1 , Group 2 , Group 3 , Group 4 , Group 5 ) 10 subject per group Groups 1-4 20 subject Group 5 . Within study group , subject randomize treatment assignment either AERAS-404 placebo control ratio 4:1 ( Groups 1-4 ) two different dose amount AERAS-404 placebo control ratio 9:9:2 ( Group 5 ) administer intramuscular injection Study Day 0 Study Day 56 . The principal investigator determine appropriate interval vaccination entire group dose time . All subject receive treatment Study Day 0 receive Study Day 56 . All subject follow safety immunogenicity evaluation 182 day . A total eleven clinic visit plan ( exclude screen ) subject</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>1 . Has complete write informed consent 2 . Is male female 3 . Is age 18 45 year Study Day 0 4 . Had BCG vaccination least 5 year ago , document medical history presence scar 5 . Has general good health , confirm medical history physical examination 6 . Has Body Mass Index ( BMI ) 19 33 7 . Agrees complete followup period 182 day require protocol 8 . Females : Agrees avoid pregnancy 28 day prior Study Day 0 followup period 182 day . Women physically capable pregnancy ( sterilize still menstruate within 1 year last menses ) must agree avoid pregnancy use acceptable method 9 . Agrees avoid elective surgery duration study 10 . Agrees stay contact investigative site study duration 11 . Completed simultaneous enrollment Aeras Vaccine Development Registry protocol 1 . Acute illness Study Day 0 2 . Axillary temperature &gt; =37.5 degrees Celsius Study Day 0 3 . Evidence significant active infection 4 . Used immunosuppressive medication within 42 day Study Day 0 5 . Received immunoglobulin blood product within 42 day Study Day 0 6 . Received investigational drug therapy investigational vaccine within 182 day Study Day 0 7 . Received inactivated influenza vaccine inactivate tickborne encephalitis vaccine within 14 day entry study , standard vaccine within 42 day Study Day 0 8 . Current chronic drug therapy include hormone replacement thyroxin , insulin 9 . History laboratory evidence past , present future possible immunodeficiency state include laboratory indication HIV infection 10 . History allergic disease reaction , include eczema 11 . Previous medical history may compromise safety subject study 12 . Evidence new acute illness may compromise safety subject study 13 . Evidence chronic hepatitis 14 . Inability discontinue daily medication except contraceptive study period 15 . History alcohol drug abuse within past 2 year 16 . Tobacco cannabis smoking three day per week 17 . Positive urine test illicit drug 18 . History evidence systemic disease physical examination 19 . History evidence active tuberculosis 20 . Shared residence within last year individual antituberculosis treatment culture smear positive tuberculosis 21 . All female : Positive urine pregnancy test screen 22 . Abnormal ( per local laboratory parameter ) chemistry hematology parameter 23 . QuantiFERONÂ®TB Gold evidence Mtb infection 24 . Received tuberculin skin test within 3 month ( 90 day ) prior Study Day 0</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>BCG Vaccinated</keyword>
	<keyword>HIV Negative</keyword>
</DOC>